Orthopediatrics (NASDAQ:KIDS) Lifted to Buy at BidaskClub

BidaskClub upgraded shares of Orthopediatrics (NASDAQ:KIDS) from a hold rating to a buy rating in a report issued on Saturday morning, BidAskClub reports.

Other equities analysts have also issued research reports about the company. ValuEngine lowered Orthopediatrics from a buy rating to a hold rating in a research note on Thursday, August 1st. Needham & Company LLC started coverage on Orthopediatrics in a research note on Wednesday, June 19th. They set a buy rating and a $53.00 target price on the stock. Finally, Zacks Investment Research lowered Orthopediatrics from a buy rating to a hold rating in a research note on Tuesday, August 13th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $44.25.

Shares of Orthopediatrics stock opened at $38.39 on Friday. The business’s fifty day simple moving average is $33.12 and its 200-day simple moving average is $38.22. Orthopediatrics has a 52 week low of $25.11 and a 52 week high of $47.82. The company has a quick ratio of 1.75, a current ratio of 2.53 and a debt-to-equity ratio of 0.24. The firm has a market cap of $559.79 million, a PE ratio of -39.99 and a beta of 0.20.

Orthopediatrics (NASDAQ:KIDS) last posted its earnings results on Wednesday, August 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.05). Orthopediatrics had a negative return on equity of 12.92% and a negative net margin of 15.77%. The firm had revenue of $18.20 million for the quarter, compared to analyst estimates of $18.44 million. During the same period in the previous year, the company posted ($0.21) EPS. Orthopediatrics’s revenue was up 20.5% on a year-over-year basis. As a group, equities analysts expect that Orthopediatrics will post -0.82 earnings per share for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Roubaix Capital LLC acquired a new stake in Orthopediatrics in the 2nd quarter valued at about $3,497,000. BlackRock Inc. raised its position in Orthopediatrics by 16.8% in the 2nd quarter. BlackRock Inc. now owns 585,555 shares of the company’s stock valued at $22,837,000 after purchasing an additional 84,205 shares in the last quarter. Wasatch Advisors Inc. raised its position in Orthopediatrics by 28.2% in the 2nd quarter. Wasatch Advisors Inc. now owns 347,598 shares of the company’s stock valued at $13,556,000 after purchasing an additional 76,534 shares in the last quarter. Calamos Advisors LLC acquired a new stake in Orthopediatrics in the 2nd quarter valued at about $2,373,000. Finally, Russell Investments Group Ltd. acquired a new stake in Orthopediatrics in the 2nd quarter valued at about $2,055,000. 48.16% of the stock is currently owned by hedge funds and other institutional investors.

Orthopediatrics Company Profile

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, RESPONSE Spine systems, Bandloc, and Pediguard.

Read More: Bollinger Bands

Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit